Can I Get GLP-1 If I'm Not Diabetic? What You Need to Know

The short answer

No, GLP-1 medications are not only for people with diabetes. Many people who use GLP-1 medications do not have type 2 diabetes. This page explains why the confusion exists, who actually qualifies for these medications, and what the clinical data shows about who is using them today.

Why the confusion: the history of GLP-1 medications

The assumption that GLP-1s are “just for diabetics” comes from their origins. The story makes sense: GLP-1 receptor agonist medications were originally developed and FDA-approved specifically for type 2 diabetes management.

Branded semaglutide came to market in 2017 for type 2 diabetes. Branded tirzepatide arrived in 2022, also approved for type 2 diabetes. For years, these medications were talked about and prescribed within the diabetes space.

But then something changed.

Providers and patients noticed that people taking these diabetes medications for weight management were experiencing significant weight loss. Researchers designed clinical trials specifically examining whether these medications could help people lose weight without a diabetes diagnosis. The data was clear.

In 2021, the FDA approved a branded version of semaglutide^[1] for chronic weight management, including in adults without diabetes. In 2023, a branded version of tirzepatide^[2] received FDA approval for the same purpose.

The diabetes association persists because these medications have been around longer in the diabetes context. But the weight management indication was studied, approved, and is now a core use case. You do not need a diabetes diagnosis to be prescribed a GLP-1 medication. If you want the specifics on dosing and indications, we cover how GLP-1 use for weight loss differs from diabetes treatment separately.

Who actually uses GLP-1 medications today

The clinical picture has shifted dramatically in the past 18 months.

A RAND survey of US adults fielded in April and May 2025^[4] found that about 12% had ever used a GLP-1 medication, to lose weight or to treat a condition such as diabetes. Use was highest among women ages 50 to 64: about 1 in 5 reported having used one. Women ages 30 to 49 were more than twice as likely as men the same age to report use.

This is not because people without diabetes are finding a loophole in a drug intended for diabetics. This is the intended use case. The medication was studied and approved for weight management, and that is now one of the main reasons it is prescribed.

The actual FDA approval criteria

FDA approval for GLP-1 weight management medications applies to adults who meet either of two conditions^[3]:

Condition 1: BMI of 30 or higher (regardless of other health factors)

Condition 2: BMI of 27 or higher, plus at least one weight-related health condition

The weight-related health conditions that count include:

• High blood pressure (hypertension)
• Elevated cholesterol or other lipid abnormalities
• Pre-diabetes or metabolic syndrome
• Type 2 diabetes (if you have it)
• Heart disease risk factors

Notice what is not on this list: you do not need a type 2 diabetes diagnosis. You do not need to have failed diet and exercise (although research suggests most people have). The approval is based on BMI and cardiometabolic risk.

Providers who prescribe compounded semaglutide or tirzepatide generally use similar clinical criteria. The provider reviews your health history, lab work, and current BMI to decide whether treatment is medically appropriate. Our GLP-1 eligibility guide walks through those criteria in more detail.

Why this matters if you are perimenopausal

The perimenopausal years (typically 40-55) are a biological turning point that many women do not anticipate. Estrogen decline does two critical things to your metabolism:

First, it shifts where your body stores fat. Before perimenopause, fat is distributed toward the hips and thighs. During perimenopause, estrogen decline causes visceral fat redistribution to the midsection and abdomen. Visceral fat is metabolically active and increases insulin resistance and cardiovascular risk, even in people without a diabetes diagnosis.

Second, estrogen decline intensifies appetite signaling. Researchers call this “food noise.” The mental urge to eat becomes more intrusive, and satiety signals become less reliable. This is not a willpower problem. It is a biological shift in how your brain regulates hunger hormones, and for many women it is the sign that the struggle is more than willpower.

GLP-1 mechanisms specifically address both of these pathways. These medications reduce appetite signaling and improve insulin sensitivity, which is particularly relevant for women navigating the metabolic changes of perimenopause. The patient guide covers GLP-1 treatment during perimenopause in more depth.

The FDA-approved weight management labels apply to adults who meet the BMI criteria, and that includes women in perimenopause. A diabetes diagnosis is not required.

Weight gain during the menopause transition is common. That shift is not a failure. It is biology. GLP-1 medications act on the appetite and blood sugar pathways that are part of that biology.

How the process should work

At most telehealth programs, the process for getting a GLP-1 prescription online starts with an intake form that covers:

• Your current height and weight (to calculate BMI)
• Your medical history (including blood pressure, cholesterol, pre-diabetes status, or other health conditions)
• Your current medications
• Your goals

A licensed provider reviews your information and decides whether GLP-1 treatment is medically appropriate for your specific situation.

Many programs do not require an in-person office visit, though some states and programs require a video or phone visit. The FDA-approved labels do not require you to have tried and failed at other methods first, although some insurers and programs ask about it. The provider makes the decision based on your health history and current clinical picture.

If the provider decides that a GLP-1 medication is appropriate, the prescription goes to a pharmacy: a retail or mail-order pharmacy for brand-name medication, or a state-licensed compounding pharmacy for a compounded one, depending on the program. If the provider decides that it is not appropriate right now, ask them to explain why and what might change that decision.

Compounded vs. FDA-approved medications: what you should know

Some telehealth programs prescribe compounded semaglutide and tirzepatide. These are prepared by state-licensed compounding pharmacies. If cost is your next question, see what compounded GLP-1 medications cost without insurance.

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they are not the same as FDA-approved brand-name GLP-1 medications. They may differ in formulation, purity, and potency.

The provider you choose reviews your health history and decides which medication, if any, is appropriate for you. Transformation Health is an independent publisher; it does not prescribe or make clinical decisions.

If you have pre-diabetes or other weight-related conditions

Pre-diabetes, metabolic syndrome, elevated cholesterol, and high blood pressure are all qualifying conditions for GLP-1 weight management medications. Having one or more of these does not require a diabetes diagnosis. In fact, these conditions are often why someone is a good candidate for GLP-1 treatment.

GLP-1 medications improve insulin sensitivity and help regulate metabolic function. For people with pre-diabetes, these effects may help lower the risk of progressing to type 2 diabetes while also supporting weight loss. Results vary.

A licensed provider considers your full clinical picture: your BMI, your lab work, your blood pressure, your metabolic markers, and your health goals. All of these factors go into the decision.

The bottom line

GLP-1 medications were approved for weight management in people without type 2 diabetes because the evidence supported that use. You do not need a diabetes diagnosis. A BMI over 30, or a BMI over 27 with at least one weight-related health condition, matches the FDA-approved label criteria. A licensed provider decides whether treatment is appropriate for you.

Many GLP-1 users are people like you: women in midlife, often in perimenopause, dealing with the biological shifts that come with aging, ready to address them with medical support.

If you have been hesitating because you thought GLP-1s were not for you, talk with a licensed provider about whether one fits your situation.

Citations

[1] FDA. Wegovy (semaglutide) injection and tablets prescribing information (NDA 215256). Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf Original approval date (06/04/2021) from Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256

[2] FDA. Zepbound (tirzepatide) injection prescribing information (NDA 217806). Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf Original approval date (11/08/2023) from Drugs@FDA: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806

[3] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Prescription Medications to Treat Overweight and Obesity.” https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity

[4] Bozick R, Donofry SD, Rancano KM. “New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.” RAND Corporation, RR-A4153-1. August 2025. https://www.rand.org/pubs/research_reports/RRA4153-1.html